Merck & Co., Inc. (NYSE:MRK) is named one of the 15 Best DRIP Stocks to Own Right Now. Morgan Stanley raises Merck’s price target to $100, maintaining an Equal Weight rating. Third-quarter results beat expectations, with Keytruda sales rising 10% to $8.1 billion in Q3 2025.

Analyst Terence Flynn raised Merck’s price target to $100, noting strong Januvia performance and lower-than-expected Keytruda and Winrevair sales. Merck projects solid growth in 2026 driven by new product launches, with operating expenses expected to rise. Flynn models 2026 EPS at $9.44.

Merck & Co., Inc. (NYSE:MRK) focuses on delivering innovative medicines, vaccines, biologic therapies, and animal health products. The company reported revenue of $17.28 billion in Q3 2025, with Keytruda sales at $8.1 billion. Merck expects worldwide sales between $64.5 billion and $65.0 billion for 2025.

While Merck (MRK) is an investment opportunity, some believe AI stocks offer greater upside potential. For those seeking undervalued AI stocks, consider exploring opportunities beyond Merck. Explore the potential of AI stocks in our free report.

Read more at Yahoo Finance: Morgan Stanley Raises Merck (MRK) Price Target to $100, Maintains Equal Weight Rating